Comparison of Alkermes plc (ALKS) and Intec Pharma Ltd. (NASDAQ:NTEC)

This is a contrast between Alkermes plc (NASDAQ:ALKS) and Intec Pharma Ltd. (NASDAQ:NTEC) based on their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alkermes plc 1.09B 3.14 173.20M -1.11 0.00
Intec Pharma Ltd. N/A 0.00 43.47M -1.32 0.00

Table 1 highlights Alkermes plc and Intec Pharma Ltd.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Alkermes plc and Intec Pharma Ltd.

Net Margins Return on Equity Return on Assets
Alkermes plc -15.89% -15.1% -9.8%
Intec Pharma Ltd. 0.00% 0% 0%

Analyst Ratings

The table delivered features the ratings and recommendations for Alkermes plc and Intec Pharma Ltd.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alkermes plc 2 5 0 2.71
Intec Pharma Ltd. 0 0 0 0.00

$29.4 is Alkermes plc’s consensus price target while its potential upside is 34.31%.

Institutional and Insider Ownership

Institutional investors owned 98.9% of Alkermes plc shares and 40.23% of Intec Pharma Ltd. shares. Alkermes plc’s share owned by insiders are 0.7%. Comparatively, Intec Pharma Ltd. has 16.08% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alkermes plc -6.88% -23.93% -22.75% -32.49% -45.56% -13.83%
Intec Pharma Ltd. -12.87% -16.85% -33.83% -10.36% 6.67% -29.97%

For the past year Alkermes plc was less bearish than Intec Pharma Ltd.

Summary

Alkermes plc beats on 6 of the 10 factors Intec Pharma Ltd.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The companyÂ’s marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa (AP-CDLD), which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients. It is also developing Accordion Pill Zaleplon (AP-ZP) that is in a Phase III clinical trial for the treatment of insomnia, including sleep induction and for enhancing of sleep maintenance; Accordion Pill, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and Accordion Pill platform with Cannabidiol and 9-Tetrahydrocannabinol, (AP-CBD/THC), which is in a Phase I clinical trial for the treatment of various indications, including low back neuropathic pain and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.